Outcomes in patients  ≥ 80 years with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy

This study assessed patient outcomes in those  <  80 and ≥ 80 years with a HPB malignancy seen at a tertiary referral centre, The Christie NHS Foundation Trust. Data on patients with a HPB malignancy were collected retrospectively between 2012 and 2017 via on-line case-note review. Survival was calculated using the Kaplan–Meier method a nd prognostic factors using log-rank analysis. Of 1421 patients, 10% were ≥ 80 years. Of patients <  80 and ≥ 80 years, 56% and 57% had pancreas cancer, 39% and 36% biliary tract cancer, and 5% and 7% had hepatocellular carcinoma, respectively. Amongst patients ≥ 80 years, 75% had an Eastern Cooperative Oncology Group performance status (ECOG PS) 0–2. Patients ≥ 80 years h ad higher rates of comorbidity; 28% received systemic anti-cancer therapy (SACT), compared with 62% of patients <  80 years. Best supportive care (BSC) was instituted in 44% of older patients, compared with 13% in those <  80 years. Of patients ≥ 80 years who received SACT, 82% received monotherapy. Median overall survival (OS) for patients receiving palliative SACT was 10.07 months (95% CI 8.89–11.08) and 10.10 months (95% CI 6.30–12.30) in patients <  80 and ≥ 80 years, respectively, p 0.41; ECOG PS (p  <  0.001) was prognostic for OS in older patients but Adult Comorbidity Evaluation-27 comorbidity score (p  =  0.07, when comparing groups of ACE score ≤ 1 andâ€...
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research